investigations was studied by comparison of findings in urine and vitreous humor in 50 autopsy cases. In addition, a cutoff value was determined for 70 drugs of toxicological relevance. The comparison study showed that vitreous humor is well-suited for qualitative screening analysis, although representativeness was not as good as urine because of less frequent metabolite detection. A total of 45 parent compounds and 24 metabolites were identified in vitreous samples; for urine, the figures were 55 and 39, respectively. The mean and median cutoff values were 0.072 and 0.023 mg/L, respectively, which are sufficient for routine casework according to the quantitative data available in the literature.
Introduction
Vitreous humor has been traditionally utilized in alcohol and glucose/lactate analyses in postmortem toxicology. There has been less interest in using it as an alternative matrix for drug analysis as the interpretation of quantitative results is complicated because of the blood-retinal barrier (1, 2) . Papers discussing vitreous drug analysis during the last decade have used target analysis approaches for specific drug groups, including amphetamines (3, 4) , benzodiazepines (5, 6) , cocaine and its metabolites (7) (8) (9) (10) , opiates (10) , LSD and metabolites (11) , cannabinoids (12) , and single substance analyses (12) (13) (14) . The applicability of vitreous use for immunological drugsof-abuse testing has also been evaluated (15) (16) (17) .
Qualitative screening analysis is a key step in postmortem forensic toxicological investigation because the ability to identify unknown agents determines the scope of the examination. Urine is the primary sample material because the time window for detection of exogenous compounds is wider in urine than in most other matrices. However, urine is not always available; in the authors' laboratory, for instance, urine samples are unavailable in approximately 15% of cases. Liver has been the traditional secondary choice, yet the range of analytes detectable in liver is somewhat limited to lipophilic drugs (18) , and tissue samples require complicated sample pretreatment, which results in increased time and cost. Vitreous humor, on the other hand, has a liquid character and resists putrefaction, which make it an attractive material for qualitative screening analysis in cases where urine is not available. In addition, because the analytes are carried from the blood stream by active and passive transportation via the blood-retinal barrier, vitreous humor is closer to blood than urine as a sample material, which makes it a suitable parallel sample material for blood.
Liquid chromatography-time-of-flight mass spectrometry (LC-TOFMS) has been used in comprehensive drug-screening procedures in the authors' laboratory on a routine basis since 2004. The applications include urine drug screening (19, 20) , urine doping agent screening (21) , and hair drug screening (22) . In this study, the suitability of vitreous humor as an alternative matrix for drug-screening purposes was studied. The representativeness of vitreous was evaluated by comparing findings in urine and vitreous, and a cutoff value was determined for 70 compounds with toxicological relevance.
LC-TOFMS
The LC-TOFMS analysis was performed as previously described (20) with minor modifications. The LC was an Agilent 1100 series instrument including a vacuum degasser, autosampler, binary pump, and column oven (Waldbronn, Germany). Separation was performed in gradient mode with a Phenomenex Luna C 18 (2) (100 × 2 mm, 3 µm) column and a 4 × 2-mm pre-column at 40°C (Torrance, CA). Mobile phase components were 5 mM ammonium acetate in 0.1% formic acid and acetonitrile. The flow rate was 0.3 mL/min. The proportion of acetonitrile was increased from 10% to 40% in 10 min, to 75% in 13.5 min, to 80% in 16 min, and held at 80% for 6 min. The post-time was 6 min and injection volume 10 µL.
The mass analyzer was a Bruker Daltonics MicrOTOF MS with an electrospray ionization (ESI) source and a six-port divert valve (Bremen, Germany). The instrument controls were performed with HyStar 3.1 and micrOTOF Control 1.1 (Bruker Daltonics) software. The nominal resolution of the instrument was 10,000. The instrument was operated in positive ion mode at m/z 50-800. The capillary voltage was 4500 V, and the capillary exit was 85 V. The nebulizer gas pressure was 1.6 bar, and the drying gas flow was 8 L/min. The drying temperature was 200°C. The spectra average was set to 2, and the summation was 12,000, corresponding to 0.6 s sample time. The transfer time was 40 µs, and the hexapole RF was 45 Vpp.
A six-point external instrument mass-scale calibration was performed prior to each sequence with sodium formate clusters by infusing 10 mM sodium hydroxide in isopropanol/0.2% formic acid (1:1, v/v). The post-run calibration of the individual data sets was enabled by injecting the calibrant at the beginning of each run via the six-port valve. The automated calibration cycle was included in the software (see Data analysis).
Data analysis
For the data analysis, TargetAnalysis 1.1 and DataAnalysis 3.4 (Bruker Daltonics) software were used. The in-house mass database included 815 monoisotopic exact masses comprising a wide chemical variety of drugs of abuse, therapeutic drugs and their metabolites, and designer drugs. Retention time information was available for approximately half of these compounds. TargetAnalysis software performed the mass-scale calibration of the data, created extracted ion chromatograms (EIC) in a m/z 0.003 window for the protonated molecule of each molecular formula included in the in-house mass database, applied peak detection and identification criteria according to mass accuracy, isotopic pattern, area, and retention time if available, and finally created an MS Excel-based result report. Isotopic pattern was expressed as SigmaFit™, which is a numerical match value calculated for the deviation of the average mass spectrum of the created EIC peak compared to the theoretical isotopic pattern of the particular molecular formula. The three identification criteria had two levels: 5 and 8 ppm for mass accuracy, 0.03 and 0.05 for SigmaFit, and 0.1 and 0.3 min for retention time. Based on these criteria, a score value for the reliability of the identification was calculated for compounds with a retention time available. The highest score, 3 (identified), required identification with better values than 5 ppm mass accuracy, 0.03 SigmaFit, and 0.1 min retention time deviation. If any of the values were in the secondary level (5-8 ppm, 0.03-0.05 SigmaFit, 0.1-0.3 min retention time) the score was 2 (possibly identified). Score 1 (tentatively identified) was given to compounds without a reference retention time. The wider identification criteria windows were applied at score 1 level.
Evaluation of the applicability of vitreous as a sample matrix
The representativeness of vitreous for drug-screening purposes was evaluated by analyzing autopsy urine and vitreous samples in parallel and comparing the number of findings in the two matrices. A total of 50 successive cases representing the routine workflow of the laboratory were selected for the study based on the availability of both urine and vitreous humor. The urine samples were analyzed with a previously described screening method based on SPE and LC-TOFMS (20), applying identification criteria described in the Data analysis section.
Determination of cutoff values
Cutoff values were determined for 70 drugs with a pooled blank vitreous sample spiked with selected drugs. The previously determined cutoffs for urine were used as starting concentrations (19) . Methanolic solutions of the reference substances (10 drugs in each sample) were evaporated to dryness prior to blank vitreous addition. The concentration was either increased or decreased until identification at the reporting criteria area (50,000) was achieved. Three replicates were analyzed at the cutoff level. 
Matrix effect
Matrix effect was studied by postcolumn infusion as described earlier by Dams et al. (23) . Seven compounds presenting varying retention behavior and polarities were selected for the study: metformine, nicotine, morphine, oxycodone, moclobemide, propranolol, and clomipramine. Early eluting compounds were emphasized based on earlier experience with urine matrix effects. The analyte in a concentration of 10 µg/mL in methanol/acetonitrile (1:1, v/v) was infused post-column via a T-piece with a flow rate of 5 µL/min. Single-analyte solutions were used. The analysis was performed by comparing the EICs of the analyte in question in two injections: the first was performed against pure mobile phase and the second against extracted pooled blank vitreous humor. The matrix effect was expressed as the ion suppression or enhancement presented as a signal intensity difference in percentage at the elution slot of the analyte.
Results and Discussion
Results from the LC-TOFMS screening analysis of urine and vitreous samples of 50 authentic cases are combined in Table  I . The total number of findings in urine and vitreous were 376 and 245, respectively. The total number of compounds identified was 97, of which 39 were (18), the current results show a much wider range of chemistries and polarities. However, some of the more polar analytes appear to be poorly detectable, most likely because of the blood-retinal barrier, as paracetamol, oxazepam, and temazepam were not detected in vitreous. Chloroquine, hydroxychloroquine, and lamotrigine were detected once in vitreous but not in the corresponding urine sample. In these cases, the blood sample was positive for the particular compound (data not shown). A noteworthy feature of vitreous was its low background noise compared to urine extracts. This reduces both instrument contamination and severe matrix effects. An example of urine-vitreous background difference is presented in Figure 1 . Table II shows a cutoff value for 70 drugs in vitreous humor. The cutoff value was not the limit of detection (LOD) by definition but a reporting criterion for the area of a detected peak. A cutoff value was used instead of LOD because fullrange data acquisition from a complex matrix often results in an excessive number of false positives if a traditional LOD definition is applied. The cutoff values varied widely from 0.007 to 0.8 mg/L with the mean and median being 0.072 and 0.023 mg/L, respectively. However, only 10 compounds had a cutoff value higher than 0.05 mg/L, and the median value was closer to the lower end of the range. The cutoff values defined in the present study for vitreous humor were similar to the LODs determined for urine in an earlier study (19) . Holmgren et al. (24) have studied the stability of drugs in vitreous and reported mean concentrations for 46 drugs in 469 cases. The concentrations varied from undetected (five compounds positive in blood but not in vitreous) to 10.9 µg/g; the overall mean and median were 1.03 and 0.15 µg/g, respectively. The cases "reflected a normal casework panorama", thus giving a realistic idea of concentrations in authentic samples. In this context, the cutoff values achieved in the present study appear adequate in general. Mackey-Bojack et al. (7) However, in suspected heroin poisonings, a target analysis for 6-MAM in blood should always be performed anyway. Thus, the inadequate cutoff in vitreous does not cause any major drawbacks. The buprenorphine cutoff of 0.1 mg/L was high, and it is obvious that the method is unfit for buprenorphine screening. Buprenorphine would require a higher capillary exit voltage, and a complimentary screening method is recommended.
Matrix effects were studied by post-column infusion of seven compounds presenting varying polarities and retention (Table  III) . Both suppression and enhancement was observed. Significant suppression occurred at 0.7-1.3 min and was -18% at its highest for morphine. This is moderate compared, for instance, to the values reported by Dams and co-workers (23) in their multimatrix study and is considered to be acceptable for a screening method. Figure 2 shows superimposed EICs for oxycodone (no suppression or enhancement), morphine (18% suppression), and nicotine (8% enhancement). The oxycodone and morphine profiles look fairly identical. However, the nicotine profile looks quite different at the beginning of the run, and indeed, some enhancement is observed. In a screening method for several hundred compounds, full validation of matrix effects is at least very complicated, if possible at all, and the presented approach gives only a general view of the phenomenon. In addition, the matrix effect variation in separate samples was evaluated by calculating the relative standard deviation (RSD) for internal standard (ISTD) peak area in 5 authentic sample series including 10 samples each. RSD varied from 18 to 33% with the average being 27%. This is a high but realistic deviation, and it is emphasized that the calculations are based on absolute areas rather than relative values typically used in quantitative target analysis evaluations.
The instrument performance was evaluated in terms of mass accuracy and mass resolution by analyzing the data in three 15-sample series collected during a three-month period with onemonth intervals. The average mass accuracy for 242 identifications of 75 compounds was 2.6 ppm or 0.64 mDa. This fulfills the 5 ppm rule for molecular formula assignment. The average mass resolution for the ISTD was 14,965, which is clearly above the instrument specification nominal resolution of 10,000 and is fairly good for a TOF instrument. However, this means that co-elution of a compound with a mass difference of ± 19.8 mDa or lower would potentially result in a false-negative result due to an increased mass error as a result of sum peak formation. Therefore, potential for a false-negative result due to limited mass resolution exists. A decent way to monitor and control this phenomenon is to follow a routine of two matrices analyzed by two independent analytical techniques, for instance blood by GC-based screening and urine/vitreous humor by TOFMS screening. In addition, we emphasize the role of selective sample preparation; with less selective sample preparation techniques, such as protein precipitation and liquid-liquid extraction, the potential for low-resolution disturbance is increased. Detailed information about fundamentals and applications of accurate mass and TOFMS technology is available elsewhere (26) .
Conclusions
Vitreous humor proved to be a feasible, easy-to-handle, and representative matrix for qualitative screening analysis. The representativeness in terms of drug and metabolite variability was lower than in urine but adequate for screening purposes. One of the advantages in postmortem work compared to clinical setting is the versatility of sample matrices available. We strongly encourage forensic toxicology laboratories to utilize this by adapting vitreous as a potential option for qualitative analysis. The cutoff values determined gave a realistic picture of the performance of the method, and although quantitative information about vitreous drug concentrations is limited in the literature, it can be concluded that the presented method is adequate for routine casework.
